DARE
NASDAQ · Pharmaceuticals
Dare Bioscience Inc
$2.07
+0.02 (+0.98%)
Financial Highlights (FY 2026)
Revenue
1.38M
Net Income
-17,954,430
Gross Margin
71.3%
Profit Margin
-1,300.7%
Rev Growth
-53.1%
D/E Ratio
2.42
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 71.3% | 71.3% | 44.5% | 44.5% |
| Operating Margin | -1,315.5% | -1,184.0% | 16.7% | 17.2% |
| Profit Margin | -1,300.7% | -1,235.6% | 17.9% | 15.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.38M | 2.95M | 6.37M | 6.18M |
| Gross Profit | 984.6K | 2.10M | 2.84M | 2.75M |
| Operating Income | -18,168,778 | -34,880,333 | 1.06M | 1.06M |
| Net Income | -17,954,430 | -34,468,828 | 1.14M | 939.3K |
| Gross Margin | 71.3% | 71.3% | 44.5% | 44.5% |
| Operating Margin | -1,315.5% | -1,184.0% | 16.7% | 17.2% |
| Profit Margin | -1,300.7% | -1,235.6% | 17.9% | 15.2% |
| Rev Growth | -53.1% | -53.1% | +7.5% | -4.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 11.51M | 11.51M | 9.41M | 9.16M |
| Total Equity | 4.75M | 4.75M | 13.13M | 13.27M |
| D/E Ratio | 2.42 | 2.42 | 0.72 | 0.69 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -15,969,646 | -32,361,697 | 1.58M | 1.73M |
| Free Cash Flow | — | — | 772.3K | 654.4K |